

AI Meets Biotech: The Future Of Protein Therapeutics With Mike Nally And Jason Silvers
17 snips May 29, 2025
Mike Nally, CEO of Generate Biomedicines, and Jason Silvers, its CFO, discuss the revolutionary impact of AI on protein therapeutics. They delve into how their 'self-driving lab' utilizes machine learning and cryo-electron microscopy to expedite drug discovery, potentially reducing development time and costs significantly. The conversation highlights their data-first approach to overcoming traditional trial-and-error in drug development, unlocking treatments for previously undruggable diseases, and transforming the economics of biotech.
AI Snips
Chapters
Transcript
Episode notes
Rethinking Protein Drug Discovery
- Traditional protein drug discovery relies heavily on trial and error, often borrowed from natural sources.
- Generate Bio uses a data-driven, engineering-first approach to revolutionize protein therapeutic development.
Integrating Sequence, Structure, Function
- Generate combines vast protein sequence and structure data with functional testing to build better models.
- This integration allows exploration of sequence, structure, and function relationships for therapeutics.
Accelerating Clinical Timelines
- Generate can take therapeutics from concept to clinic in 18-24 months, greatly shortening traditional timelines.
- Early-stage cost to drug candidate nomination reduces from millions to hundreds of thousands of dollars.